New Zealand · Delayed Price · Currency is NZD BLIS Technologies Company Description
BLIS Technologies Limited develops and sells probiotics in New Zealand, the Asia Pacific, Europe, the Middle East, Africa, and North America.
It offers BLIS K12, an oral probiotic that supports ear, nose, and throat health, as well as immunity and bad breath; BLIS M18, an oral probiotic for teeth and gums health; and BLIS Q24, a probiotic that balances the skin microbiome and restores skin’s health.
The company’s products are used in various health areas, including ear, nose, throat, immune, dental, and skin, as well as pet oral.
It exports its products. The company was formerly known as Tarn Holdings Limited and changed its name to BLIS Technologies Limited in August 2000.
BLIS Technologies Limited was incorporated in 2000 and is headquartered in Dunedin, New Zealand.
| Country | New Zealand |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Scott Johnson |
Contact Details
Address: 399 Moray Place Dunedin, 9016 New Zealand | |
| Phone | 64 3 474 0988 |
| Website | blis.co.nz |
Stock Details
| Ticker Symbol | BLT |
| Exchange | New Zealand Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | NZD |
| ISIN Number | NZBLTE0002S8 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Scott Johnson | Chief Executive Officer |
| Richard Wingham | Chief Financial Officer |